Monoclonal antibodies (mAbs) presently dominate the biotherapeutic market. However, biotherapeutics in general, and mAbs in particular, are expensive therapies and outside the realm of affordability for most of the world. In an attempt to lower their cost of manufacturing, a novel in-house non-protein A continuous platform has recently been reported for mAb purification. In this paper, we perform an in-depth evaluation of the process economics to assess the impact of removing the protein A step on the cost of goods (COGs).

中文翻译：

---

蛋白质的贡献 迈向连续生产单克隆抗体疗法的商品成本的一步

单克隆抗体 (mAb) 目前主导着生物治疗市场。然而，一般而言，生物治疗药物，尤其是单克隆抗体，是昂贵的治疗药物，超出了世界大部分地区的可负担范围。为了降低制造成本，最近报道了一种用于 mAb 纯化的新型内部非蛋白 A 连续平台。在本文中，我们对工艺经济学进行了深入评估，以评估去除蛋白 A 步骤对商品成本 (COG) 的影响。